RT Journal Article
T1 Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
A1 Sáez-Lara, Maria Jose
A1 Robles-Sanchez, Candido
A1 Ruiz-Ojeda, Francisco Javier
A1 Plaza-Diaz, Julio
A1 Gil, Angel
K1 Probiotics
K1 Randomized clinical trial
K1 Obesity
K1 Insulin resistance
K1 Metabolic syndrome X
K1 Type 2 diabetes
K1 Non-alcoholic fatty liver disease
K1 Synbiotics
K1 Glucemia
K1 Índice de masa corporal
K1 Metabolismo de los hidratos de carbono
K1 Moléculas de adhesión celular
K1 Diabetes mellitus tipo 2
K1 Ayuno
K1 Alimentos funcionales
K1 Humanos
K1 Resistencia a la insulina
K1 Lípidos
K1 Síndrome x metabólico
K1 Enfermedad del hígado graso no alcohólico
K1 Obesidad
K1 Probióticos
K1 Estrés fisiológico
K1 Simbióticos
AB The use of probiotics and synbiotics in the prevention and treatment of different disorders has dramatically increased over the last decade. Both probiotics and synbiotics are well known ingredients of functional foods and nutraceuticals and may provide beneficial health effects because they can influence the intestinal microbial ecology and immunity. The present study reviews the effects of probiotics and synbiotics on obesity, insulin resistance syndrome (IRS), type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) in human randomized clinical trials. Select probiotics and synbiotics provided beneficial effects in patients with obesity, mainly affecting the body mass index and fat mass. Some probiotics had beneficial effects on IRS, decreasing the cell adhesion molecule-1 levels, and the synbiotics decreased the insulin resistance and plasma lipid levels. Moreover, select probiotics improved the carbohydrate metabolism, fasting blood glucose, insulin sensitivity and antioxidant status and also reduced metabolic stress in subjects with T2D. Some probiotics and synbiotics improved the liver and metabolic parameters in patients with NAFLD. The oral intake of probiotics and synbiotics as co-adjuvants for the prevention and treatment of obesity, IRS, T2D and NAFLD is partially supported by the data shown in the present review. However, further studies are required to understand the precise mechanism of how probiotics and synbiotics affect these metabolic disorders.
PB MDPI
YR 2016
FD 2016-06-13
LK http://hdl.handle.net/10668/2257
UL http://hdl.handle.net/10668/2257
LA en
NO Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. International Journal of Molecular Sciences. 2016; 17(6):928.
NO Journal Article; Review; This article belongs to the Special Issue Advances in Molecular Research of Functional and Nutraceutical Food)
DS RISalud
RD Apr 7, 2025